DJIA 16,058.35 -469.68 -2.84%
NASDAQ 4,636.11 -140.40 -2.94%
S&P 500 1,913.85 -58.33 -2.96%
market minute promo

Biogen Idec (NASDAQ: BIIB)

292.50 -4.80 (-1.61%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

BIIB $292.50 -1.61%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $292.22
Previous Close $297.30
Daily Range $291.26 - $301.98
52-Week Range $265.00 - $480.18
Market Cap $68.8B
P/E Ratio 20.07
Dividend (Yield) $0.00 (0.0%)
Volume 2,498,363
Average Daily Volume 3,406,936
Current FY EPS $15.92




Drug Makers

Biogen Idec (BIIB) Description

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies. Website:

News & Commentary

We Believe Healthcare's Next Biotech Buyout Target Is…

Which biotech company will be the next buyout target? To answer this question, we turned to three of our healthcare contributors, and this is what they had to say.

Biogen: 'A Nice Little Trade' Or Heading To New Lows?

Jim Cramer -- A Fed Rate Hike Won't Stop Profit Opportunities

Applied Genetic Meets Enrolment Milestone in XLRS Study

3 Stocks Pushing The Health Care Sector Downward

Get Ready For The Second Round Of The Market Downturn

Cramer Remains Cautious on Stocks

Biogen And Gilead Sciences Catch The Eye Of Short Sellers

IVW, NKE, BIIB, KMI: Large Outflows Detected at ETF

2 Reasons I'm Bullish for Biogen's Future

Two potential mega-blockbuster opportunities make this the biotech stock to watch.

See More BIIB News...

BIIB's Top Competitors

BIIB $292.50 (-1.61%)
Current stock: BIIB
AMGN $147.46 (-2.85%)
Current stock: AMGN
GILD $101.49 (-3.41%)
Current stock: GILD
$0.00 (0.00%)
Current stock: